Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Applied Genetic Tech (AGTC)

Applied Genetic Tech (AGTC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,503
  • Shares Outstanding, K 18,171
  • Annual Sales, $ 24,190 K
  • Annual Income, $ -21,300 K
  • 60-Month Beta 2.58
  • Price/Sales 1.52
  • Price/Cash Flow N/A
  • Price/Book 0.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.40
  • Low Estimate -0.53
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -24.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +9.30%
on 07/03/19
4.08 -4.90%
on 06/20/19
unch (unch)
since 06/19/19
3-Month
3.54 +9.60%
on 05/15/19
4.95 -21.62%
on 04/25/19
-0.67 (-14.73%)
since 04/18/19
52-Week
2.26 +71.68%
on 12/21/18
7.50 -48.27%
on 10/01/18
-0.27 (-6.51%)
since 07/19/18

Most Recent Stories

More News
Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.

HZNP : 24.10 (-2.15%)
ALNY : 75.37 (-0.69%)
ACOR : 6.90 (+0.15%)
AGTC : 3.88 (unch)
Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.

HZNP : 24.10 (-2.15%)
ALNY : 75.37 (-0.69%)
ACOR : 6.90 (+0.15%)
AGTC : 3.88 (unch)
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.

ALNY : 75.37 (-0.69%)
AGTC : 3.88 (unch)
AMGN : 178.39 (-0.64%)
MRTX : 106.00 (+0.10%)
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug

Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).

CRBP : 6.05 (-2.42%)
ALNY : 75.37 (-0.69%)
KDMN : 2.48 (-4.98%)
AGTC : 3.88 (unch)
ObsEva Ends Recruitment in Second Uterine Fibroids Study

ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.

OBSV : 10.05 (-2.71%)
ABBV : 68.54 (+0.42%)
ACOR : 6.90 (+0.15%)
AGTC : 3.88 (unch)
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.

ALNY : 75.37 (-0.69%)
ACOR : 6.90 (+0.15%)
AGTC : 3.88 (unch)
CPRX : 4.05 (-2.17%)
Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu

Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.

ANIK : 40.62 (-1.12%)
AGTC : 3.88 (unch)
NVAX : 4.61 (-0.65%)
SNY : 41.95 (unch)
Alnylam Presents New Data for RNAi Therapeutic Onpattro

Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.

ANIK : 40.62 (-1.12%)
ALNY : 75.37 (-0.69%)
ACOR : 6.90 (+0.15%)
AGTC : 3.88 (unch)
Epizyme Announces Positive Interim Data on Lead Candidate

Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat.

ANIK : 40.62 (-1.12%)
ACOR : 6.90 (+0.15%)
AGTC : 3.88 (unch)
EPZM : 12.73 (-0.39%)
AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire

AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.

ANIK : 40.62 (-1.12%)
ACOR : 6.90 (+0.15%)
AGTC : 3.88 (unch)
AMAG : 8.74 (-2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade AGTC with:

Business Summary

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis...

See More

Key Turning Points

2nd Resistance Point 4.09
1st Resistance Point 3.99
Last Price 3.88
1st Support Level 3.82
2nd Support Level 3.75

See More

52-Week High 7.50
Fibonacci 61.8% 5.50
Fibonacci 50% 4.88
Fibonacci 38.2% 4.26
Last Price 3.88
52-Week Low 2.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar